Structure-activity relationships and binding model of novel aromatase inhibitors.

Abstract

The use of aromatase inhibitors is an established therapy for oestrogen-dependent breast cancer in postmenopausal women. However, the sole commercially available aromatase inhibitor, aminoglutethimide, is not very selective. We have therefore developed fadrozole hydrochloride and CGS 20,267, which are both currently under clinical evaluation. This report… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.